Despite Spike, Why Investors Should Still Avoid MannKind Like the Plague

Gemini Therapeutics Banks $42.5M to Bring Precisio

Gemini Therapeutics Banks $42.5M to Bring Precisio

MannKind could be sent to dilute shares in a significant manner, warns Maxim analyst Jason Kolbert in a research note released today.

MannKind Corporation could be sent to dilute shares in a significant manner, warns Maxim analyst Jason Kolbert in a research note released today. Should you avoid MNKD? As far as the analyst is concerned, the answer is clearly yes.

MORE ON THIS TOPIC